AAAAAA

   
Results: 1-22 |
Results: 22
Safety aspects of growth hormone replacement in adults
Authors: Johannsson, G Jorgensen, JOL
Citation: G. Johannsson et Jol. Jorgensen, Safety aspects of growth hormone replacement in adults, GROWTH H I, 11(2), 2001, pp. 59-71
Body composition and quality of life as markers of the efficacy of growth hormone replacement therapy in adults
Authors: Svensson, J Johannsson, G Bengtsson, BA
Citation: J. Svensson et al., Body composition and quality of life as markers of the efficacy of growth hormone replacement therapy in adults, HORMONE RES, 55, 2001, pp. 55-60
Is the somatotropic axis related to sympathetic nerve activity in healthy ageing men?
Authors: Sverrisdottir, YB Johannsson, G Jungersten, L Wallin, BG Elam, M
Citation: Yb. Sverrisdottir et al., Is the somatotropic axis related to sympathetic nerve activity in healthy ageing men?, J HYPERTENS, 19(11), 2001, pp. 2019-2024
Long-term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonist
Authors: van der Lely, AJ Hutson, RK Trainer, PJ Besser, GM Barkan, AL Katznelson, L Klibanski, A Herman-Bonert, V Melmed, S Vance, ML Freda, PU Stewart, PM Friend, KE Clemmons, DR Johannsson, G Stavrou, S Cook, DM Phillips, LS Strasburger, CJ Hacker, S Zib, KA Davis, RJ Scarlett, JA Thorner, M
Citation: Aj. Van Der Lely et al., Long-term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonist, LANCET, 358(9295), 2001, pp. 1754-1759
A prospective investigation of quality of life and psychological well-being after the discontinuation of GH treatment in adolescent patients who had GH deficiency during childhood
Authors: Wiren, L Johannsson, G Bengtsson, BA
Citation: L. Wiren et al., A prospective investigation of quality of life and psychological well-being after the discontinuation of GH treatment in adolescent patients who had GH deficiency during childhood, J CLIN END, 86(8), 2001, pp. 3494-3498
A prospective study of 5 years of GH replacement therapy in GH-deficient adults: Sustained effects on body composition, bone mass, and metabolic indices
Authors: Gotherstrom, G Svensson, J Koranyi, J Alpsten, M Bosaeus, I Bengtsson, BA Johannsson, G
Citation: G. Gotherstrom et al., A prospective study of 5 years of GH replacement therapy in GH-deficient adults: Sustained effects on body composition, bone mass, and metabolic indices, J CLIN END, 86(10), 2001, pp. 4657-4665
Baseline characteristics and the effects of five years of GH replacement therapy in adults with GH deficiency of childhood or adulthood onset: A comparative, prospective study
Authors: Koranyi, J Svensson, J Gotherstrom, G Sunnerhagen, KS Bengtsson, BA Johannsson, G
Citation: J. Koranyi et al., Baseline characteristics and the effects of five years of GH replacement therapy in adults with GH deficiency of childhood or adulthood onset: A comparative, prospective study, J CLIN END, 86(10), 2001, pp. 4693-4699
GH is needed for the maturation of muscle mass and strength in adolescents
Authors: Hulthen, L Bengtsson, BA Sunnerhagen, KS Hallberg, L Grimby, G Johannsson, G
Citation: L. Hulthen et al., GH is needed for the maturation of muscle mass and strength in adolescents, J CLIN END, 86(10), 2001, pp. 4765-4770
Growth hormone and ageing
Authors: Johannsson, G Svensson, J Bengtsson, BA
Citation: G. Johannsson et al., Growth hormone and ageing, GROWTH H I, 10, 2000, pp. 25-30
A nine-month, placebo-controlled study of the effects of growth hormone treatment on lipoproteins and LDL size in abdominally obese men
Authors: Svensson, J Bengtsson, BA Taskinen, MR Wiklund, O Johannsson, G
Citation: J. Svensson et al., A nine-month, placebo-controlled study of the effects of growth hormone treatment on lipoproteins and LDL size in abdominally obese men, GROWTH H I, 10(3), 2000, pp. 118-126
GH and bone - Experimental and clinical studies
Authors: Isaksson, OGP Ohlsson, C Bengtsson, BA Johannsson, G
Citation: Ogp. Isaksson et al., GH and bone - Experimental and clinical studies, ENDOCR J, 47, 2000, pp. S9-S16
What happens when growth hormone is discontinued at completion of growth? Metabolic aspects
Authors: Johannsson, G
Citation: G. Johannsson, What happens when growth hormone is discontinued at completion of growth? Metabolic aspects, J PED END M, 13, 2000, pp. 1321-1326
Treatment of growth hormone deficiency in adults
Authors: Bengtsson, BA Johannsson, G Shalet, SM Simpson, H Sonken, PH
Citation: Ba. Bengtsson et al., Treatment of growth hormone deficiency in adults, J CLIN END, 85(3), 2000, pp. 933-937
Sympathetic neural burst amplitude distribution - A more specific indicator of sympathoexcitation in human heart failure
Authors: Sverrisdottir, YB Rundqvist, B Johannsson, G Elam, M
Citation: Yb. Sverrisdottir et al., Sympathetic neural burst amplitude distribution - A more specific indicator of sympathoexcitation in human heart failure, CIRCULATION, 102(17), 2000, pp. 2076-2081
Growth hormone and syndrome x
Authors: Johannsson, G Marin, P Johansson, JO Bengtsson, BA
Citation: G. Johannsson et al., Growth hormone and syndrome x, CONT ENDOC, 19, 2000, pp. 247-260
Double-blind, placebo-controlled study of growth hormone treatment in elderly patients undergoing chronic hemodialysis: Anabolic effect and functional improvement
Authors: Johannsson, G Bengtsson, BA Ahlmen, J
Citation: G. Johannsson et al., Double-blind, placebo-controlled study of growth hormone treatment in elderly patients undergoing chronic hemodialysis: Anabolic effect and functional improvement, AM J KIDNEY, 33(4), 1999, pp. 709-717
Effect of growth-hormone therapy on early atherosclerotic changes in GH-deficient adults
Authors: Bengtsson, BA Johannsson, G
Citation: Ba. Bengtsson et G. Johannsson, Effect of growth-hormone therapy on early atherosclerotic changes in GH-deficient adults, LANCET, 353(9168), 1999, pp. 1898-1899
Treatment of obese subjects with the oral growth hormone secretagogue MK-677 affects serum concentrations of several lipoproteins, but not lipoprotein(a)
Authors: Svensson, J Jansson, JO Ottosson, M Johannsson, G Taskinen, MR Wiklund, O Bengtsson, BA
Citation: J. Svensson et al., Treatment of obese subjects with the oral growth hormone secretagogue MK-677 affects serum concentrations of several lipoproteins, but not lipoprotein(a), J CLIN END, 84(6), 1999, pp. 2028-2033
Growth hormone (GH) therapy in GH-deficient adults influences the responseto a dietary load of cholesterol and saturated fat in terms of cholesterolsynthesis, but not serum low density lipoprotein cholesterol levels
Authors: Leonsson, M Oscarsson, J Bosaeus, I Lundgren, BK Johannsson, G Wiklund, O Bengtsson, BA
Citation: M. Leonsson et al., Growth hormone (GH) therapy in GH-deficient adults influences the responseto a dietary load of cholesterol and saturated fat in terms of cholesterolsynthesis, but not serum low density lipoprotein cholesterol levels, J CLIN END, 84(4), 1999, pp. 1296-1303
Discontinuation of growth hormone (GH) treatment: Metabolic effects in GH-deficient and GH-sufficient adolescent patients compared with control subjects
Authors: Johannsson, G Albertsson-Wikland, K Bengtsson, BA
Citation: G. Johannsson et al., Discontinuation of growth hormone (GH) treatment: Metabolic effects in GH-deficient and GH-sufficient adolescent patients compared with control subjects, J CLIN END, 84(12), 1999, pp. 4516-4524
Is GH therapy indicated in the metabolic syndrome?
Authors: Johannsson, G Bjorntorp, P Bengtsson, BA
Citation: G. Johannsson et al., Is GH therapy indicated in the metabolic syndrome?, CHALLENGES IN GROWTH HORMONE THERAPY, 1999, pp. 264-281
Growth hormone therapy and fracture risk in the growth hormone-deficient adult
Authors: Johannsson, G Ohlsson, C
Citation: G. Johannsson et C. Ohlsson, Growth hormone therapy and fracture risk in the growth hormone-deficient adult, BAIL CLIN E, 12(2), 1998, pp. 233-250
Risultati: 1-22 |